KEYNOTE-522方案中辅助帕博利珠单抗治疗三阴性乳腺癌的必要性反思
KEYNOTE-522试验的无事件生存和总生存获益使帕博利珠单抗进入II-III期三阴性乳腺癌的新辅助和辅助治疗。但术后缺乏第二次随机分配,无法证明辅助阶段免疫治疗本身的获益。本文评述现有证据、争议、知识空白和未来方向,涉及pCR与残留病灶人群、辅助免疫治疗毒性及成本等问题。
要点
- KEYNOTE-522未设术后二次随机,辅助帕博利珠单抗的独立获益未被证实。
- pCR和残留病灶人群的辅助免疫治疗必要性均存疑。
- 部分癌种(含TNBC)研究提示辅助免疫治疗可能无获益。
核心结论
- KEYNOTE-522确立了辅助帕博利珠单抗为当前标准治疗,但辅助部分本身的获益并未得到证明。
研究设计与样本
- 本文为评论性文章(commentary),讨论早期三阴性乳腺癌辅助免疫治疗的现有证据、争议与未来展望。
主要发现
- KEYNOTE-522的无事件生存和总生存获益使帕博利珠单抗纳入II-III期TNBC的新辅助和辅助治疗。
- 术后缺乏第二次随机分配,使辅助阶段免疫治疗的必要性在pCR和残留病灶患者中均无法确认。
- 部分癌种(包括TNBC)的研究提示辅助免疫治疗可能不提供获益。
- 尚无研究专门评估新辅助化疗联合免疫治疗后辅助免疫治疗的作用。
- 肿瘤浸润淋巴细胞基线存在、循环肿瘤DNA缺失或特定分子亚型与pCR相关并被提议为局限性TNBC免疫治疗试验的预测生物标志物,但KEYNOTE-522未发表相关数据。
临床怎么用
- 目前辅助帕博利珠单抗按KEYNOTE-522方案作为标准治疗使用,但其辅助阶段的独立价值仍需进一步证据明确。
局限性
- KEYNOTE-522缺乏术后第二次随机分配,无法单独评估辅助帕博利珠单抗的获益。
- 尚无研究专门评估新辅助化疗联合免疫治疗后辅助免疫治疗的作用。
- KEYNOTE-522未发表肿瘤浸润淋巴细胞、循环肿瘤DNA或分子亚型等生物标志物数据以阐明辅助治疗获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gains in event-free and overall survival from the KEYNOTE-522 trial have incorporated pembrolizumab into the neoadjuvant and adjuvant armamentarium for stage II-III triple-negative breast cancer (TNBC). However, the lack of a second randomization to pembrolizumab after surgery raises the question of whether the adjuvant phase of this immunotherapeutic agent is necessary, both in patients who achieve a pathological complete response (pCR) and in those with residual disease. Thus, the KEYNOTE-522 design established the use of adjuvant pembrolizumab as current standard of care without demonstrated benefit of the adjuvant part. Some studies in patients with specific types of cancer, including TNBC, suggest that adjuvant immunotherapy may not provide a benefit. Furthermore, no study has evaluated the role of adjuvant immunotherapy specifically following neoadjuvant chemoimmunotherapy. Additionally, concerns regarding chronic toxicities and the use of health care resources including costs of the adjuvant treatment have raised concerns in the oncologic community. Baseline presence of tumor-infiltrating lymphocytes and absence of circulating tumor DNA or specific molecular subtypes are associated with pCR and have been proposed as biomarkers predicting outcomes in trials of immunotherapy in localized TNBC, but no data on these biomarkers from the KEYNOTE-522 trial have been published to clarify the benefit of adjuvant pembrolizumab. This commentary discusses the available evidence, ongoing controversies, knowledge gaps and future perspectives regarding adjuvant immunotherapy in early TNBC.
引用
- Liutti VT, Wildiers H, Sonke GS, et al. Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary? Eur J Cancer. 2026. PMID: 42810150. doi:10.1016/j.ejca.2026.117064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。